Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “autologous” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 59
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 59 pipeline programs matching "autologous" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

59 results for “autologous” Back to intelligence hub

Search results

Page 2 of 3
  1. GARM-Autism Adults

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial
  2. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial
  3. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials
  4. Intracavernosal administration of autologous ADRC

    The First People's Hospital of Lianyungang

    Erectile Dysfunction

    phase 2 other completed

    1 trial
  5. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial
  6. LIMBAL STEM CELLS, AUTOLOGOUS

    Fondazione Telethon ETS

    low back pain

    phase 2 small molecule active

    1 trial
  7. LZRSE-Col7A1 Engineered Autologous Epidermal Sheets

    ABEONA THERAPEUTICS INC.

    Epidermolysis Bullosa Dystrophica

    phase 2 mab completed

    1 trial
  8. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial
  9. Transplantation of Autologous stem cell [MNCs] .

    Hospital Authority, Hong Kong

    Spinal Cord Injury.

    phase 2 mab active

    1 trial
  10. autologous adipose-derived mesenchymal stem cell transplantation

    Hospital Authority, Hong Kong

    Aging Problems

    phase 2 mab active

    1 trial
  11. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial
  12. autologous dendritic cells pulsed with tumor lysate antigen Vaccine

    NORTHWEST BIOTHERAPEUTICS INC

    Giant Cell Glioblastoma

    phase 2 mab terminated

    1 trial
  13. autologous mesenchymal stem cells implantation

    Teva Pharma GmbH

    Tibial Fracture

    phase 2 other completed

    1 trial
  14. autologous skin fibroblasts

    United Therapeutics Europe Ltd

    Wounds and Injuries

    phase 2 mab active

    1 trial
  15. idecabtagene vicleucel

    Celgene Europe Limited

    Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

    phase 2 small molecule active

    1 trial
  16. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial
  17. Autologous Bone Marrow-derived Mononuclear Cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease

    phase 1 mab completed

    1 trial
  18. Autologous Engineered Urethral Construct

    United Therapeutics Europe Ltd

    Urologic Diseases

    phase 1 mab active

    1 trial
  19. Autologous Human Schwann Cell

    United Therapeutics Europe Ltd

    Peripheral Nerve Injury

    phase 1 mab active

    1 trial
  20. Autologous Natural Killer Cell Therapy

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial
  21. Autologous differentiated myocyte transplantation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metabolic Disease

    phase 1 mab active

    1 trial
  22. Autologous mononuclear cells

    Regeneron Ireland Designated Activity Company (DAC)

    Congenital Heart Disease, SRV Dependent

    phase 1 mab active

    1 trial
  23. Autologous tissue engineered corpora

    United Therapeutics Europe Ltd

    Urologic Diseases

    phase 1 mab active

    1 trial
  24. Autologous tumor-infiltrating lymphocyte cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 mab terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.